Key stats
About iShares NASDAQ US Biotechnology UCITS ETF
Home page
Inception date
Oct 19, 2017
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
BlackRock Asset Management Ireland Ltd.
ISIN
IE00BYXG2H39
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.85%
Health Technology96.05%
Commercial Services1.65%
Technology Services1.30%
Health Services0.84%
Process Industries0.02%
Bonds, Cash & Other0.15%
Cash0.08%
Mutual fund0.07%
Miscellaneous0.00%
Stock breakdown by region
North America83.78%
Europe15.88%
Asia0.26%
Oceania0.07%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BTEC1/N invests in stocks. The fund's major sectors are Health Technology, with 96.05% stocks, and Commercial Services, with 1.65% of the basket. The assets are mostly located in the North America region.
BTEC1/N top holdings are Vertex Pharmaceuticals Incorporated and Gilead Sciences, Inc., occupying 7.90% and 7.82% of the portfolio correspondingly.
BTEC1/N assets under management is 12.33 B MXN. It's risen 16.92% over the last month.
BTEC1/N fund flows account for 1.47 B MXN (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, BTEC1/N doesn't pay dividends to its holders.
BTEC1/N shares are issued by BlackRock, Inc. under the brand iShares. The ETF was launched on Oct 19, 2017, and its management style is Passive.
BTEC1/N expense ratio is 0.35% meaning you'd have to pay 0.35% of your investment to help manage the fund.
BTEC1/N follows the NASDAQ Biotechnology Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BTEC1/N invests in stocks.
BTEC1/N price has risen by 8.50% over the last month, and its yearly performance shows a 1.37% increase. See more dynamics on BTEC1/N price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 8.09% over the last month, showed a 13.19% increase in three-month performance and has increased by 2.59% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 8.09% over the last month, showed a 13.19% increase in three-month performance and has increased by 2.59% in a year.
BTEC1/N trades at a premium (1.00%) meaning the ETF is trading at a higher price than the calculated NAV.